Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.
FOLFIRINOX
Gemcitabine Nab-Paclitaxel
LAPC
NACT
conversion therapy
locally advanced pancreatic cancer
neoadjuvant chemotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Jul 2019
13 Jul 2019
Historique:
received:
19
06
2019
revised:
09
07
2019
accepted:
10
07
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
The optimal therapeutic strategy for locally advanced pancreatic cancer patients (LAPC) has not yet been established. Our aim is to evaluate how surgery after neoadjuvant treatment with either FOLFIRINOX (FFN) or Gemcitabine-NabPaclitaxel (GemNab) affects the clinical outcome in these patients. LAPC patients treated at our institution were retrospectively analysed to reach this goal. The group characteristics were similar: 35 patients were treated with the FOLFIRINOX regimen and 21 patients with Gemcitabine Nab-Paclitaxel. The number of patients undergoing surgery was 14 in the FFN group (40%) and six in the GemNab group (28.6%). The median Disease-Free Survival (DFS) was 77.10 weeks in the FFN group and 58.65 weeks in the Gem Nab group (
Identifiants
pubmed: 31337045
pii: cancers11070981
doi: 10.3390/cancers11070981
pmc: PMC6678351
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : MFAG2018-21505
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG2018-21339
Références
Dig Liver Dis. 2019 Jul;51(7):1043-1049
pubmed: 31000479
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210
pubmed: 30865919
Eur Radiol. 2017 Jul;27(7):3104-3116
pubmed: 27896469
Cancers (Basel). 2019 Feb 26;11(3):
pubmed: 30813624
Ann Surg Oncol. 2015 Oct;22(11):3512-21
pubmed: 26065868
J Surg Oncol. 2018 Nov;118(6):1021-1026
pubmed: 30259526
Cancers (Basel). 2019 Mar 07;11(3):
pubmed: 30866547
Ann Surg Oncol. 2017 Jul;24(7):2023-2030
pubmed: 28213792
Ann Surg Oncol. 2015 Apr;22(4):1153-9
pubmed: 25358667
Pancreatology. 2015 Nov-Dec;15(6):667-73
pubmed: 26412296
Ann Surg. 2015 Jan;261(1):18-20
pubmed: 25599323
BMC Cancer. 2012 May 29;12:199
pubmed: 22642850
Mol Clin Oncol. 2017 Jun;6(6):963-967
pubmed: 28588798
Science. 2011 Mar 25;331(6024):1612-6
pubmed: 21436454
Onco Targets Ther. 2019 Apr 23;12:3077-3085
pubmed: 31118666
Ann Surg. 2021 Mar 1;273(3):579-586
pubmed: 30946073
J Hematol Oncol. 2017 Mar 28;10(1):76
pubmed: 28351381
Ann Surg Oncol. 2017 Sep;24(9):2734-2743
pubmed: 28560601
J Transl Med. 2014 Apr 21;12:102
pubmed: 24745825
Cancer Chemother Pharmacol. 2018 May;81(5):815-821
pubmed: 29502139
Med Oncol. 2013 Mar;30(1):361
pubmed: 23271209
Pathol Oncol Res. 2017 Oct;23(4):753-759
pubmed: 28062950
Eur Radiol. 2018 Oct;28(10):4265-4273
pubmed: 29679211
Oncologist. 2019 Mar;24(3):301-e93
pubmed: 30459238
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Cancers (Basel). 2019 Jan 15;11(1):
pubmed: 30650521
Ann Surg. 2019 Aug;270(2):340-347
pubmed: 29596120
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Ann Surg Oncol. 2016 Dec;23(13):4352-4360
pubmed: 27370653
Eur J Surg Oncol. 2018 Oct;44(10):1619-1623
pubmed: 30146251
Cancer. 1987 Nov 1;60(9):2284-303
pubmed: 3326653
Onco Targets Ther. 2016 Jul 28;9:4681-6
pubmed: 27555786
J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1
pubmed: 17114007
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Cancer Res Ther. 2017 Apr-Jun;13(2):240-245
pubmed: 28643741
J Clin Oncol. 2011 Nov 1;29(31):4105-12
pubmed: 21969502
J Radiat Oncol. 2013 Dec;2(4):413-425
pubmed: 25755849
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Pancreas. 2004 Apr;28(3):293-5
pubmed: 15084974
Ann Surg. 1987 Sep;206(3):358-65
pubmed: 3632096
Ann Surg Oncol. 2008 Aug;15(8):2081-8
pubmed: 18461404
J Gastrointest Oncol. 2018 Dec;9(6):982-988
pubmed: 30603116
Oncologist. 2013;18(5):543-8
pubmed: 23657686
Ann Surg. 2015 Jan;261(1):12-7
pubmed: 25599322
Medicine (Baltimore). 2018 Dec;97(50):e13592
pubmed: 30558029
Br J Cancer. 2016 Mar 29;114(7):737-43
pubmed: 27022826
Lancet Oncol. 2016 Jun;17(6):801-810
pubmed: 27160474
Ann Surg. 2016 Sep;264(3):457-63
pubmed: 27355262
J Am Coll Surg. 2008 Oct;207(4):510-9
pubmed: 18926452
Cancer Chemother Pharmacol. 2018 Mar;81(3):609-614
pubmed: 29362902
Ann Oncol. 2008 Sep;19(9):1592-9
pubmed: 18467316
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Pancreas. 2015 May;44(4):515-21
pubmed: 25872127
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
Br J Cancer. 2014 Sep 9;111(6):1132-8
pubmed: 25072261
Clin Res Hepatol Gastroenterol. 2019 Nov;43(6):663-668
pubmed: 31029644
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1212-20
pubmed: 26350368
J Surg Oncol. 2015 Jun;111(8):1028-34
pubmed: 26073887
J Clin Oncol. 2005 Feb 20;23(6):1228-36
pubmed: 15718320
Anticancer Res. 2018 Jul;38(7):4035-4039
pubmed: 29970528
Oncologist. 2016 Feb;21(2):178-87
pubmed: 26834159
Cancer Control. 2004 Jan-Feb;11(1):23-31
pubmed: 14749620
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Pancreatology. 2019 Mar;19(2):296-301
pubmed: 30638853
HPB (Oxford). 2019 Feb;21(2):219-225
pubmed: 30093144